Henan Taloph Pharmaceutical Stock Co.,Ltd engages in the manufacture and sale of pharmaceutical preparations and Chinese herbal medicine slices in China. The company offers Shuanghuanglian oral liquid series, Shuangjinlian mixture, children's heat-clearing and cough-relieving oral liquid series, pediatric antipyretic oral liquid, Jiaweishanxiang Zhengqi compound preparation, honeysuckle dew, danshen oral liquid, Shengmai Yin, pediatric compound chicken gizzard chewable tablets, Chewable tablets, huperzine A tablets, Wuzi Yanzong oral liquid, compound motherwort oral liquid, etc. It is also involved in pharmaceutical research and development, and medicine and medicinal materials distribution. The company's medicine preparations are used in the treatment of respiratory system, cardiovascular and cerebrovascular, digestive system, nervous system, menstrual system, reproductive system, and gynecological diseases. Henan Taloph Pharmaceutical Stock Co.,Ltd was formerly known as Henan Joyline & Joysun Pharmaceutical Stock Co., Ltd. The company was founded in 1998 and is based in Zhengzhou, China.
Research context
Henan Taloph Pharmaceutical Stock Co.,Ltd appears in PyInvesting’s Shanghai Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Henan Taloph Pharmaceutical Stock Co.,Ltd is currently in a long term uptrend where the price is trading 2.7% above its 200 day moving average.
From a valuation standpoint, the stock is 77.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.2.
Henan Taloph Pharmaceutical Stock Co.,Ltd's total revenue rose by 7.5% to $317M since the same quarter in the previous year.
Its net income has dropped by 80.3% to $1M since the same quarter in the previous year.
Finally, its free cash flow grew by 37.1% to $-22M since the same quarter in the previous year.
Based on the above factors, Henan Taloph Pharmaceutical Stock Co.,Ltd gets an overall score of 4/5.